Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

Dow:

Nasdaq:

S&P 500:

GRFS

$8.100.75%0.06

Grifols Sa Adr (GRFS)

Date: O: H: L: C: Vol:

Grifols Sa Adr Borsa (GRFS) Ultime notizie

JPMorgan cuts Grifols target from USD 10.00 to USD 9.00 for Grifols stock - ad-hoc-news.de

Plasma Demand Supports Grifols, S.A.’s (GRFS) Path Back to Financial Strength - Yahoo Finance

Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance Australia

Grifols, S.A. (GRF.MC) Stock Price, News, Quote & History - Yahoo! Finance Canada

Return on assets % of Grifols, S.A. Pref Class B – HAN:G0F0 - TradingView

Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance Singapore

Grifols, S.A. - Reuters

Grifols says Canada plasma license suspension has no impact on ongoing operations - Reuters

Grifols stock trades below recent highs as valuation focus grows - ad-hoc-news.de

Grifols SA Lobbying Profile, 2024 - OpenSecrets

Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.

Grifols stock edges lower as investors weigh recent earnings and valuation - ad-hoc-news.de

Grifols SA Lobbyists, 2024 - opensecrets.org

Grifols SA Lobbying Profile, 2020 - OpenSecrets

Operating margin % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView

Return on invested capital % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView

Return on equity % of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView

Price to earnings ratio of Grifols, S.A. Sponsored ADR Class A – HAM:G0F - TradingView

G0F Forecast — Price Target — Prediction for 2027 - TradingView

G0F Stock Price and Chart — HAM:G0F - TradingView

Grifols stock holds below $8 as half-year 2026 earnings highlight margin progress - ad-hoc-news.de

Grifols stock holds in single digits as Q2 2026 earnings miss consensus by a small margin - Ad-hoc-news.de

ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView

Grifols Up Over 6%, on Pace for Largest Percent Increase Since May 2025 -- Data Talk - Moomoo

ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - tradingview.com

ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView

Grifols stock trades below $8 as investors weigh earnings outlook - Ad-hoc-news.de

Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency - barchart.com

Grifols ADRs Drop 4% to $7.87 as GRFS Nears Key Support at $7.48 - Insider Buying Alerts - vinanet.vn

Grifols, S.A. Class A Revenue Breakdown – BME:GRF - TradingView

Grifols (GRFS) reshapes board, Audit and Strategy Committees - Stock Titan

Grifols shares jump after Q2 results exceed expectations - Investing.com

Grifols, S.A. Sponsored ADR Class A Revenue Breakdown – MUN:G0F - TradingView

Grifols, S.A. (GRFS) Stock Rises on Q2 2026 Earnings - Quiver Quantitative

Grifols (GRFS) Q2 2026 Earnings Call Transcript - The Globe and Mail

Grifols, S.A. (GRFS) Stock Rises on Q2 2026 Earnings - Quiver Quantitative

Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ... - finance.yahoo.com

Grifols SA Lobbying Profile, 2022 - OpenSecrets

Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Grifols SA expected to post earnings of 24 cents a share - Earnings Preview - TradingView

Grifols, S.A. (GRFS) Stock Price, News, Quote & History - Yahoo! Finance Canada

[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.

Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com - Investing.com UK

ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView

G0FB Forecast — Price Target — Prediction for 2027 - TradingView

Price to earnings forward of Grifols, S.A. Class A – BME:GRF - TradingView

GRFS - Grifols SA ADR Options - Finviz

GRFS - Grifols SA ADR Volatility & Greeks - Finviz

GRFS - Grifols SA ADR Volatility & Greeks - Finviz

GRFS - Grifols SA ADR Latest SEC Filings - Finviz

Simile a GRFS

AMRN$12.114.91%

MIRA$0.54854.04%

SCLX$1.8510.19%

MDCX$1.8812.56%